美国Celltrion将FDA批准的高度生物类似药Adalimumab-Aaty纳入Costco会员处方计划,扩大治疗选择并降低医疗保健成本. Celltrion USA integrates FDA-approved high-concentration biosimilar Adalimumab-Aaty into Costco Member Prescription Program, expanding treatment options and lowering healthcare costs.

美国Celltrion公司已将其FDA批准的生物仿制药,Adalimumab-Aaty,一种高度,无酸盐版本的Humira,纳入Costco会员处方计划. Celltrion USA has integrated its FDA-approved biosimilar, Adalimumab-Aaty, a high-concentration, citrate-free version of Humira, into the Costco Member Prescription Program. Adalimumab-Aaty治疗各种煽动性疾病,包括风湿性关节炎、青少年病原体性关节炎和克罗恩病。 Adalimumab-Aaty treats various inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn's disease. 这种包容性旨在扩大治疗选择,改善获得生物类同服务的机会,帮助降低病人的保健费用。 This inclusion aims to expand treatment options, improve access to biosimilars, and help reduce healthcare costs for patients.